|Bid||0.00 x 900|
|Ask||0.00 x 1200|
|Day's Range||43.33 - 43.71|
|52 Week Range||37.43 - 50.04|
|Beta (3Y Monthly)||0.75|
|PE Ratio (TTM)||26.98|
|Forward Dividend & Yield||1.86 (4.34%)|
|1y Target Est||48.67|
just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.
Drugmakers Sanofi and Regeneron said on Tuesday that they received positive results for their Dupixent product, which treats eczema and is seen as a key driver of future revenues. Sanofi and Regeneron ...
Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.
Bausch + Lomb/International, a subsidiary of Bausch Health (BHC), generated net revenues of $1.21 billion in the second quarter, compared to $1.22 billion in the second quarter of 2017. This increase reflects ~4.0% YoY (year-over-year) organic growth.
BRIDGEWATER, N.J., Oct. 11, 2018 /PRNewswire/ -- If you find yourself spending more on health care than ever, you're not alone. Americans under the age of 65 who were insured through their employer spent more than ever on health care, and spending grew faster in 2016 than in recent years. For some patients, the problem is a lack of health insurance or a sudden gap in coverage that may come with a job change.
Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise including the 5% increase in its operating revenue and the 2% favorable impact of foreign exchange. Alcon announced in September 2018 that it would be locating its future headquarters in Geneva, Switzerland, following the completion of the proposed spinoff from Novartis.
Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.
The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.
BRIDGEWATER, N.J., Oct. 9, 2018 /PRNewswire/ -- Companies across industries from IT to biopharma have long emphasized the importance of recruiting and maintaining women in jobs in the so-called STEM fields – Science, Technology, Engineering, and Math. "We know from our own experience, and demonstrated by research, that gender diversity creates greater value, and that an inclusive culture is far more likely to be innovative and agile," says Cristina Santos, Sanofi's Head of Inclusion & Diversity and EEO North America. More than half of the highly qualified women in STEM jobs will eventually quit because of factors like lack of opportunity, bias, or isolation by male peers.
Just look at biotech company Vaxart (NASDAQ:VXRT), whose shares soared by a sizzling 78% to $5.25. Of course, the company got some favorable news from one of its clinical trials. In a Phase 2 study, patients taking its H1 influenza vaccine showed a 39% reduction in illness compared to those taking a placebo.
Johnson & Johnson (JNJ) has a market capitalization of $373.8 billion. Although the company has had several litigation issues in recent years, it has registered strong quarterly results and has had some key launches and approvals.
Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.
Sangamo Therapeutics (SGMO), a clinical stage biotechnology firm, is focused on developing gene-based therapies using industry-leading technology platforms in gene therapy, cell therapy, genome editing, and gene regulation. The company has collaborations with a number of leading pharmaceuticals firms including Gilead Sciences (GILD), Sanofi (SNY), and Pfizer (PFE) to develop a wide range of genomic therapies. In this part, we’ll discuss Sangamo Therapeutics’ recent recommendations and target prices from Wall Street analysts.